Auris Medical Holding Stock

Auris Medical Holding ROE 2024

Auris Medical Holding ROE

0

Ticker

EARS

ISIN

BMG070252017

WKN

A2PJN3

In 2024, Auris Medical Holding's return on equity (ROE) was 0, a 0% increase from the 0 ROE in the previous year.

Auris Medical Holding Aktienanalyse

What does Auris Medical Holding do?

Auris Medical Holding Ltd is a biopharmaceutical company that was founded in 2013 and is headquartered in Zug, Switzerland. The company specializes in the development and marketing of products in the field of hearing and hearing impairment. The history of Auris Medical Holding Ltd began with the founding of the company by Thomas Meyer and Daniel J. Salomon, both of whom had extensive experience in the biotech industry and investment banking. The company went public on the NASDAQ stock exchange in 2014 and has since expanded its business steadily. Auris Medical's business model is based on the development of innovative therapies and medications for disorders in the ENT field. The company focuses on the needs of patients with hearing and hearing impairment due to neurosensory disorders. In this area, there are currently only a few approved therapies, which represents a significant unmet medical need. Auris Medical divides its activities into two divisions: the development of clinical therapies and the marketing of products for the treatment of tinnitus and hearing loss. In the field of clinical therapies, the company specializes in the development of medications for restoring hearing. Among other things, Auris Medical is working on the development of AM-111, a treatment for acute inner ear damage that can lead to sudden hearing loss. Auris Medical also operates its own distribution chain, which offers products for the treatment of tinnitus and hearing loss. These products are marketed under the name Tinnitool and include devices for relieving tinnitus and hearing loss. The company also offers audiology services to perform individual audiological evaluations. Overall, Auris Medical Holding Ltd has a wide range of products aimed at the needs of patients with hearing and hearing impairment. From medications to symptom relief products to diagnostic services, the company is able to address various aspects of the health issue. As an innovative company, Auris Medical Holding Ltd invests heavily in research and development of new therapies and medications. The company collaborates with leading experts in the field of hearing and hearing impairment to improve its technologies and products. Additionally, the company aims to expand into further regions to reach a broader patient base. In summary, Auris Medical Holding Ltd is an emerging company in the field of hearing and hearing impairment. With a wide product portfolio tailored to the needs of patients, the company invests in research and development to develop new therapies and medications. Through its innovation and strong partnerships in the field of hearing and hearing impairment, the company plans to establish itself as a leading company in this field. Auris Medical Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Auris Medical Holding's Return on Equity (ROE)

Auris Medical Holding's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Auris Medical Holding's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Auris Medical Holding's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Auris Medical Holding’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Auris Medical Holding stock

What is the ROE (Return on Equity) of Auris Medical Holding this year?

The ROE of Auris Medical Holding this year is 0 undefined.

How has the Return on Equity (ROE) of Auris Medical Holding developed compared to the previous year?

The ROE of Auris Medical Holding has increased by 0% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Auris Medical Holding?

A high ROE indicates that Auris Medical Holding generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Auris Medical Holding?

A low ROE can indicate that Auris Medical Holding is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Auris Medical Holding affect the company?

A change in ROE (Return on Equity) of Auris Medical Holding can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Auris Medical Holding?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Auris Medical Holding?

Some factors that can influence Auris Medical Holding's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Auris Medical Holding pay?

Over the past 12 months, Auris Medical Holding paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Auris Medical Holding is expected to pay a dividend of 0 CHF.

What is the dividend yield of Auris Medical Holding?

The current dividend yield of Auris Medical Holding is .

When does Auris Medical Holding pay dividends?

Auris Medical Holding pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Auris Medical Holding?

Auris Medical Holding paid dividends every year for the past 0 years.

What is the dividend of Auris Medical Holding?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Auris Medical Holding located?

Auris Medical Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Auris Medical Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Auris Medical Holding from 9/21/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did Auris Medical Holding pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of Auris Medical Holding in the year 2023?

In the year 2023, Auris Medical Holding distributed 0 CHF as dividends.

In which currency does Auris Medical Holding pay out the dividend?

The dividends of Auris Medical Holding are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Auris Medical Holding

Our stock analysis for Auris Medical Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Auris Medical Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.